MiMedx Follow Up Study Of DFU Patients Shows 94% Of Patients Remained Healed After Nine To Twelve Months

 MiMedx Follow Up Study Of DFU Patients Shows 94% Of Patients Remained Healed
                         After Nine To Twelve Months

Follow Up Study Accepted For Publication In Wound Medicine

PR Newswire

MARIETTA, Ga., Nov. 19, 2013

MARIETTA, Ga., Nov. 19, 2013 /PRNewswire/ --MiMedx Group, Inc. (NASDAQ:
MDXG), an integrated developer, manufacturer and marketer of patent protected
regenerative biomaterials and bioimplants processed from human amniotic
membrane, announced today that its study "Dehydrated Human Amnion/Chorion
Membrane Allografts in Patients with Chronic Diabetic Foot Ulcers: A Long-term
Follow-up Study"has been accepted for publication in Wound Medicine. The
study manuscript was authored byCharles M. Zelen, DPM, FACFAS, FACFAOM,
FAPWCA; Thomas E. Serena MD, FACS; and Donald E. Fetterolf, MD, MBA, FACP.

This study is the long term follow-up from a previously completed randomized
controlled trial (RCT) involving patients with diabetic foot ulcers (DFU). In
this follow up study, the patients whose DFU wounds healed after treatment
with EpiFix® in the initial RCT and the subsequent crossover study were

Eighteen of 22 eligible patients returned for follow-up examination, which was
conducted 9 to 12 months after primary wound closure with EpiFix®. Clinical
record review was conducted with IRB approval and patient consent. Of the
eighteen patients studied, only one patient had recurrent DFU during the
follow-up period, while 17, or 94.4%, remained fully healed. These findings
support the long-term effectiveness of dehydrated human amnion/chorion
membrane ("dHACM") for treatment of DFU. The study concluded that dHACM is a
clinically viable and economically feasible treatment option that should be
considered by clinicians who treat diabetic pedal ulcers.

Parker H. "Pete" Petit, Chairman and CEO said, "The identification and
implementation of an ideal treatment regimen for DFUs is an increasingly
common issue faced by clinicians. Therapies that promote rapid and complete
healing, thus reducing the risk for infection and amputation, can
substantially improve quality of life while decreasing financial burdens. A
competitor recently announced that the clinical study of their products showed
that only 52% of their patients bothhealed in 12 weeks and remained healed at
the subsequent 12 week follow-up. An optimal treatment for DFU would be one
that supports both rapid and long-term healing. With 94.4% of DFUs remaining
healed approximately one year after treatment, we believe our EpiFix®
allograft is a clinically effective and economic solution to these needs."

Bill Taylor, President and COO, stated, "Human amniotic membrane has been used
as an allograft to treat wounds for over a century. However, our proprietary
PURION® process has led to the development of our EpiFix® dHACM allograft.
Studies have shown strong clinical and cost effectiveness of EpiFix® for
healing of DFUs, Venus leg ulcers, and wounds that have failed to heal with
other treatment modalities with minimal, if any, waste. Use of competitive
skin substitutes routinely result in waste of over 80% of their graft because
they come in only one very large size, which is generally at least 15 times
greater than the median DFU. EpiFix® has size appropriate grafts and
consequently, there is very little waste."

"This clinical study is one of many in our series of publications that
chronicle the clinical and cost effectiveness of our PURION® processed EpiFix®
allografts," concluded Petit.

The follow-up study is expected to be e-published during the last week of
November in Wound Medicine
(http://www.elsevier.com/journals/wound-medicine/2213-9095). The initial RCT
entitled "A prospective randomised comparative parallel study of amniotic
membrane wound graft in the management of diabetic foot ulcers," was published
in the International Wound Journal, and the electronic publication can be
found at http://onlinelibrary.wiley.com/doi/10.1111/iwj.12097/full. The
subsequent "crossover" study, "An evaluation of healing with the use of
dehydrated human amniotic membrane allografts in patients with chronic
diabetic foot ulcers,"  was published in Journal of Wound Care, and the
electronic publication can be found at

About MiMedx
MiMedx® is an integrated developer, manufacturer and marketer of patent
protected regenerative biomaterial products and bioimplants processed from
human amniotic membrane. "Innovations in Regenerative Biomaterials" is the
framework behind our mission to give physicians products and tissues to help
the body heal itself. Our biomaterial platform technologies include AmnioFix®
and EpiFix®, our tissue technologies processed from human amniotic membrane
that is derived from donated placentas. Through our donor program, mothers
delivering full-term Caesarean section births can elect in advance of delivery
to donate the placenta in lieu of having it discarded as medical waste. We
process the human amniotic membrane utilizing our proprietary PURION® process,
to produce a safe and effective implant. MiMedx® is the leading supplier of
amniotic tissue, having supplied over 190,000 allografts to date to
distributors and OEMs for application in the Wound Care, Surgical, Sports
Medicine, Ophthalmic and Dental sectors of healthcare.

Safe Harbor Statement
This press release includes statements that look forward in time or that
express management's beliefs, expectations or hopes. Such statements are
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements include, but are not limited
to the long-term clinical and cost effectiveness of EpiFix®. These statements
are based on current information and belief, and are not guarantees of future
performance. Among the risks and uncertainties that could cause actual
results to differ materially from those indicated by such forward-looking
statements include the potential that EpiFix® will not perform as expected or
will not gain acceptance in the medical community, and the risk factors
detailed from time to time in the Company's periodic Securities and Exchange
Commission filings, including, without limitation, its 10-K filing for the
fiscal year ended December 31, 2012, and the Company's most recent Form 10-Q.
By making these forward-looking statements, the Company does not undertake to
update them in any manner except as may be required by the Company's
disclosure obligations in filings it makes with the Securities and Exchange
Commission under the federal securities laws.

SOURCE MiMedx Group, Inc.

Website: http://mimedx.com
Contact: Michael Senken, Phone: (770) 651-9100
Press spacebar to pause and continue. Press esc to stop.